Cargando…
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker
PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopath...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916110/ https://www.ncbi.nlm.nih.gov/pubmed/27390646 http://dx.doi.org/10.1186/s40064-016-2513-x |
_version_ | 1782438773476294656 |
---|---|
author | Guo, Lei Li, Wenbin Zhu, Xinxin Ling, Yun Qiu, Tian Dong, Lin Fang, Yi Yang, Hongying Ying, Jianming |
author_facet | Guo, Lei Li, Wenbin Zhu, Xinxin Ling, Yun Qiu, Tian Dong, Lin Fang, Yi Yang, Hongying Ying, Jianming |
author_sort | Guo, Lei |
collection | PubMed |
description | PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA expression in tumor tissues from 183 TNBC patients respectively. Fluorescence in situ hybridization analysis was performed on PD-L1 strong expression samples to assess copy number on chromosome 9p24.1 of CD274 gene. RESULTS: Expression of PD-L1 by immune cells was observed in 4.9 % of TNBC, while expression by tumor cells accounted for 8.7 %. There was a high concordance in PD-L1 protein expression and PDL1 mRNA expression. Samples with PD-L1 strong expression were found to have a CD274 gene copy number gain. PD-L1 expression was correlated with higher tumor grade, but was independent of menopausal status, lymph nodes metastasis, histological subtype and tumor size. In addition, we used precise stratification of PD-L1 expression on tumor or immune cells of certain breast cancer subtype and suggested that patients with PD-L1 expression in basal-like tumors by immune cells or with CD274 gene copy number gain had a longer disease-specific overall survival. CONCLUSIONS: Our findings may promote the more precise analysis of PD-L1 expression in breast cancer and aid the selection of patients who may benefit from immune therapy. |
format | Online Article Text |
id | pubmed-4916110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-49161102016-07-07 PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker Guo, Lei Li, Wenbin Zhu, Xinxin Ling, Yun Qiu, Tian Dong, Lin Fang, Yi Yang, Hongying Ying, Jianming Springerplus Research PURPOSE: To estimate the therapeutic potential of PD-L1 inhibition in breast cancer, we evaluated the prevalence and significance of PD-L1 protein expression with a validated antibody and CD274 gene alternation in a large cohort of triple negative breast cancer (TNBC) and correlated with clinicopathological data and patients overall survival. METHODS: Immunohistochemistry and in situ mRNA hybridization was used to detect PD-L1 protein and mRNA expression in tumor tissues from 183 TNBC patients respectively. Fluorescence in situ hybridization analysis was performed on PD-L1 strong expression samples to assess copy number on chromosome 9p24.1 of CD274 gene. RESULTS: Expression of PD-L1 by immune cells was observed in 4.9 % of TNBC, while expression by tumor cells accounted for 8.7 %. There was a high concordance in PD-L1 protein expression and PDL1 mRNA expression. Samples with PD-L1 strong expression were found to have a CD274 gene copy number gain. PD-L1 expression was correlated with higher tumor grade, but was independent of menopausal status, lymph nodes metastasis, histological subtype and tumor size. In addition, we used precise stratification of PD-L1 expression on tumor or immune cells of certain breast cancer subtype and suggested that patients with PD-L1 expression in basal-like tumors by immune cells or with CD274 gene copy number gain had a longer disease-specific overall survival. CONCLUSIONS: Our findings may promote the more precise analysis of PD-L1 expression in breast cancer and aid the selection of patients who may benefit from immune therapy. Springer International Publishing 2016-06-21 /pmc/articles/PMC4916110/ /pubmed/27390646 http://dx.doi.org/10.1186/s40064-016-2513-x Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Guo, Lei Li, Wenbin Zhu, Xinxin Ling, Yun Qiu, Tian Dong, Lin Fang, Yi Yang, Hongying Ying, Jianming PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title_full | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title_fullStr | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title_full_unstemmed | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title_short | PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
title_sort | pd-l1 expression and cd274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916110/ https://www.ncbi.nlm.nih.gov/pubmed/27390646 http://dx.doi.org/10.1186/s40064-016-2513-x |
work_keys_str_mv | AT guolei pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT liwenbin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT zhuxinxin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT lingyun pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT qiutian pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT donglin pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT fangyi pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT yanghongying pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker AT yingjianming pdl1expressionandcd274genealterationintriplenegativebreastcancerimplicationforprognosticbiomarker |